Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) insider Suresh K. Durgam sold 4,367 shares of the firm’s stock in a transaction on Monday, January 11th. The shares were sold at an average price of $32.12, for a total value of $140,268.04. Following the sale, the insider now directly owns 21,851 shares of the company’s stock, valued at approximately $701,854.12. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
NASDAQ:ITCI opened at $33.84 on Thursday. The stock has a market cap of $2.71 billion, a P/E ratio of -10.51 and a beta of 1.43. The stock’s 50-day moving average is $28.64 and its 200-day moving average is $25.02. Intra-Cellular Therapies, Inc. has a 1-year low of $10.94 and a 1-year high of $34.40.
Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Saturday, November 14th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.00) by $0.21. The company had revenue of $7.37 million for the quarter, compared to analysts’ expectations of $6.52 million. Intra-Cellular Therapies had a negative return on equity of 48.27% and a negative net margin of 1,985.32%. Equities analysts forecast that Intra-Cellular Therapies, Inc. will post -3.27 earnings per share for the current fiscal year.
ITCI has been the subject of a number of research reports. ValuEngine raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Tuesday, December 22nd. Cantor Fitzgerald lifted their target price on Intra-Cellular Therapies from $53.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, December 29th. Royal Bank of Canada decreased their target price on Intra-Cellular Therapies from $43.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, November 2nd. BidaskClub upgraded Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Wednesday, December 23rd. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Intra-Cellular Therapies in a research report on Monday, October 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $42.89.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Read More: What is Forex?
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.